Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1855129 | 0.90 | CA2 (0.39) | CA2CA1CA9 | |
| SCHEMBL2434048 | 0.86 | CA2 (0.34) | CA2CA1CA9 | |
| SCHEMBL12643973 | 0.85 | CA2 (0.36) | CA2CA1CA9 | |
| SCHEMBL2487801 | 0.84 | CA2 (0.33) | CA2CA1CA9 | |
| SCHEMBL3032133 | 0.82 | CA2 (0.34) | CA2CA1CA9 | |
| SCHEMBL9141595 | 0.82 | CA2 (0.34) | CA2CA1CA9 | |
| SCHEMBL12477390 | 0.82 | CA2 (0.34) | CA2CA1CA9 | |
| SCHEMBL12476991 | 0.82 | CA2 (0.34) | CA2CA1CA9 | |
| SCHEMBL12476413 | 0.82 | CA2 (0.34) | CA2CA1CA9 | |
| SCHEMBL7899371 | 0.81 | CA1 (0.33) | CA2CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 276 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4466266-B1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | TRANSNEURAL THERAPEUTICS INC (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-3950682-B1 | PREPARATION METHOD FOR AMIDE COMPOUNDS AND USE THEREOF IN MEDICAL FIELD | SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO LTD (CN) | 2026-02-11 | — | — | EP | disclosed |
| US-12486268-B2 | Fused heterocycles as 5-HT2A receptor agonists | Transneural Therapeutics, Inc. (US) | 2025-12-02 | — | — | US | disclosed |
| US-12473289-B2 | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | AMGEN INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-12473298-B2 | Amide compounds, preparation method therefor, and use thereof in the medical field | SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO., LTD. (CN) | 2025-11-18 | — | — | US | disclosed |
| US-12459944-B2 | Fused heterocycles as 5-HT2A receptor agonists | Transneural Therapeutics, Inc. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-3848362-B1 | HETEROARYL AZOLE COMPOUND AND PEST CONTROL AGENT | NIPPON SODA CO (JP) | 2025-10-29 | — | — | EP | disclosed |
| US-12448396-B2 | Methods of using heterocyclic compounds as Delta-5 Desaturase inhibitors | AMGEN INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250243199-A1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | Transneural Therapeutics, Inc. (US) | 2025-07-31 | — | — | US | disclosed |
| WO-2025121409-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC AND AROMATIC CARBOCYCLIC DERIVATIVE HAVING SEROTONIN RECEPTOR BINDING ACTIVITY | シオノギ－アプニメッド スリープ サイエンス、エルエルシー | 2025-06-12 | — | — | WO | disclosed |
| EP-1501827-A2 | PIPERIDINYL-AND PIPERAZINYL-SULFONYLMETHYL HYDROXAMIC ACID AND THEIR USE AS PROTEASE INHIBITORS | Pharmacia Corporation (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20050009838-A1 | Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors | PHARMACIA CORPORATION | 2005-01-13 | — | — | US | disclosed |
| US-20040138065-A1 | Malononitrile compounds and their use as pesticides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1385817-A2 | MALONONITRILE COMPOUNDS AND THEIR USE AS PESTICIDES | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2004-02-04 | — | — | EP | disclosed |
| WO-2004009528-A1 | 2,4-DIHYDROXYBENZOIC ACID DERIVATIVES | J. Uriach Y Compañia S.A. (ES) | 2004-01-29 | — | — | WO | disclosed |
| WO-2003091247-A2 | PIPERIDINYL-AND PIPERAZINYL-SULFONYLMETHYL HYDROXAMIC ACIDS AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-11-06 | — | — | WO | disclosed |
| WO-2002090320-A2 | MALONONITRILE COMPOUNDS AND THEIR USE AS PESTICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-11-14 | — | — | WO | disclosed |
| US-6090805-A | Tocolytic oxytocin receptor antagonists | MERCK & CO., INC. (US) | 2000-07-18 | — | — | US | disclosed |
| US-5968938-A | Piperazine oxytocin receptor antagonists | MERCK & CO., INC. (US) | 1999-10-19 | — | — | US | disclosed |
| US-5814378-A | ACRYLATED ESTER OF A BIPHENYL COMPOUND | SHARP KABUSHIKI KAISHA (JP) | 1998-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459944-B2 | Fused heterocycles as 5-HT2A receptor agonists | HTR2A, HTR2C, HTR5A | CA2 4134/4885CA1 4337/4885CA9 4771/4885 |
| US-12473298-B2 | Amide compounds, preparation method therefor, and use thereof in the medical field | EZH2, IKZF2, EZH1 | CA2 3998/4885CA1 2962/4885CA9 4198/4885 |
| US-12448396-B2 | Methods of using heterocyclic compounds as Delta-5 Desaturase inhibitors | SCD5, SCD, FADS2 | CA2 3618/4885CA1 4368/4885CA9 2597/4885 |
| US-20040138065-A1 | Malononitrile compounds and their use as pesticides | CBR1, MAL2, CBR3 | CA2 118/4885CA1 754/4885CA9 404/4885 |
| US-20250243199-A1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | HTR2A, HTR2C, HTR5A | CA2 4134/4885CA1 4337/4885CA9 4771/4885 |
| US-20050009838-A1 | Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors | MMP1, PREP, MMP3 | CA2 101/4885CA1 79/4885CA9 147/4885 |
| US-12473289-B2 | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | SCD5, SCD, FADS2 | CA2 3512/4885CA1 4414/4885CA9 2576/4885 |
| US-12486268-B2 | Fused heterocycles as 5-HT2A receptor agonists | HTR2A, HTR2C, HTR5A | CA2 4134/4885CA1 4337/4885CA9 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.